英文名称: Human glioblastoma cell line A172 总访问: 115 国产/进口: 国产 半年访问: 5 产地/品牌: 雅吉生物 产品类别: 细胞株/菌种 规格: T25瓶/1*10^6 最后更新: 2025-3-3 货号: YS015C 参考报价: 1800 立即询价 电话咨询 [发表评论] [本类其他产品] [本类其他供应商] [收藏] 分享:微信...
Cell lines A172 and T98G varied in morphology and surface markers expression. High level of mesenchymal markers CD90 and CD105, fibroblast activation protein, and tenascin C was detected for A172 cell line. Both cell lines expressed high level of 伪2 smooth muscle actin gene. Data ...
Human Cell line 1D3人类粒细胞系 OKT 11杂交瘤细胞抗 HUVEC人脐静脉血管内皮细胞 CEM-C7人外周血急性淋巴细胞白血病 MH7A类风湿关节炎滑膜成纤维细胞 PC14/B肺癌细胞株 H226br肺癌细胞 N9小鼠小胶质细胞 HVSMC人血管平滑肌细胞 bEnd.3小鼠脑微血管内皮细胞 capan-1胰腺癌细胞 BJ 人皮肤成纤维细胞 c2c12...
人类粒细胞系HumanCellline1D3 猪肾传代细胞系IBRS-2 人纤维肉瘤细胞系JH-2 人子宫内膜腺癌细胞系KLE 人二倍体细胞系KMB-17 人胚肾上皮细胞系KiMA 人胚肺细胞系KuMA 草鱼肝脏细胞系L8824 人结肠腺癌细胞系LS174T 小鼠胚胎干细胞LT04 小鼠乳腺癌细胞系MA782/5S-8101 ...
Y-1 cell line细胞系;细胞传代方法:1:2传代;细胞形态特性:上皮样;细胞生长特性:贴壁生长;细胞背景资料:详见相关文献介绍 SW 1990[SW-1990,SW1990]细胞系;细胞传代方法:1:2-1:3传代;每周换液2-3次;细胞形态特性:详见细胞说明书;细胞生长特性:贴壁或悬浮,详见细胞说明书部分;细胞背景资料:详见相关文献介绍 H...
Cell lines A172 and T98G varied in morphology and surface markers expression. High level of mesenchymal markers CD90 and CD105, fibroblast activation protein, and tenascin C was detected for A172 cell line. Both cell lines expressed high level of α2 smooth muscle actin gene. Data ...
英文名称 A172-RFP-Puro polyclonal stable cell line 产品货号 VGC-0165-002P 中文名称 RFP 标记的 A172 稳转株 Lot number A172-10A2P 细胞规格 复苏细胞 (T25细胞瓶) 或1 × 106 细胞冻存细胞 细胞形态 成纤维细胞样 生长特性 贴壁生长 细胞株 构建流程 (1)构建目的基因过表达慢病毒重组质粒,并包装慢...
Heat-induced apoptosis in human glioblastoma cell line A172. Hyperthermia has been clinically applied to some types of brain tumors. However, the detailed mechanisms of this growth inhibition are not clear. The effec... Fuse,K W,Yoon,... - 《Neurosurgery》 被引量: 114发表: 1998年 MicroRNA...
APA172Hu01Active Platelet Factor 4 (PF4)Cell culture; Activity Assays. RPA172Hu02Recombinant Platelet Factor 4 (PF4)Positive Control; Immunogen; SDS-PAGE; WB. AntibodiesPAA172Hu01Polyclonal Antibody to Platelet Factor 4 (PF4)WB; IHC; ICC; IP. ...
[1] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial. Baohui Han, et al. JAMA Oncol. ...